Iovance stock crashed Thursday, undercutting its 50-day line, on new durability questions facing its experimental lung cancer treatment. Roughly a quarter of patients with a form of metastatic lung cancer responded to treatment with Iovance Biotherapeutics' (IOVA) drug, lifileucel. But the company didn't note how long patients responded to treatment nor did it outline specific safety and tolerability results. Both…